News & Events All CategoriesNewsEvents Meet the Healix Team at ACAAI Stop by booth #746 to learn about how we help practices like yours provide a full continuum of care for your patients. Healix Collaborative Research at ACG 2021 Healix is proud to participate in collaborative research with our clients at the 2021 American College of Gastroenterology (ACG) Annual Meeting. Healix Collaborative Research at IgNS Healix is excited to once again present our collaborative Research at IgNS National Conference 2021. NORM 2021 Annual Meeting Stop by our booth at the NORM Annual Meeting to learn about our office-based infusion services for your Rheumatology practice. IDWeek 2021 Visit Healix at IDWeek 2021, Sept. 29 – Oct. 3, to learn why Healix is the premier provider of outpatient infusion management services. 2021 Annual Meeting of the Florida Society of Neurology Healix is excited to participate at the 2021 Annual Meeting of the Florida Society of Neurology, September 24-26, 2021, in Orlando, Florida. COVID-19 Pandemic Initial Impact on Outpatient Intravenous Antibiotic Therapy An analysis of the initial impact of the COVID-19 pandemic on the rate of hospital patient referrals for outpatient antimicrobial therapy COVID-19 pandemic impact on infusion utilization Physician office infusion centers deliver lower cost and higher adherence — even during a pandemic. Happy National Pharmacy Week (October 18-24) from Healix! In celebration of Pharmacy Week 2020, the entire team at Healix would like to sincerely thank all pharmacists, pharmacy technicians, and pharmacy personnel for their service and dedication to the pharmacy profession. Healix Research at the American College of Allergy, Asthma, & Immunology (ACAAI) Annual Meeting Healix is proud to participate in clinical research at the American College of Allergy, Asthma, & Immunology (ACAAI) Annual Meeting November 12-16, 2020 Healix Collaborative Research with the GI Alliance at the American College of Gastroenterology (ACG) Annual Meeting 2020 Healix is a proud participant of collaborative research with the GI Alliance at the 2020 American College of Gastroenterology (ACG) Annual Meeting. Visit the poster presentation at this year’s virtual conference October 23 – 28, 2020. Join Healix at IDWeek 2020 Visit the Healix virtual booth at IDWeek October 22 – 24, 2020 to learn how we can help infectious disease practices like yours to provide unparalleled infusion patient care. Healix Research at the Immunoglobulin National Society (IgNS) 9th National Conference 2020 Healix is excited to present our research data on Cutaquig® at the Immunoglobulin National Society (IgNS) 9th National Conference 2020. Healix Demonstrates Hospital Avoidance with Provision of Outpatient Antimicrobial Therapy (OPAT): A Leader in the Field for Over 30 Years Healix Infusion Therapy, LLC has demonstrated success in achieving hospital avoidance when providing outpatient antimicrobial therapy (OPAT) to patients with serious infections through physician offices. Healix Announces First Real-World Study of Immune Globulin Subcutaneous 16.5% (Cutaquig®) Featured in the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Healix Infusion Therapy is pleased to announce that its collaborative research study regarding Immune Globulin Subcutaneous 16.5% (Cutaquig®) is now accessible in the AAAAI Annual Meeting Virtual Poster Hall. Happy National Nurses Week (May 6-12) from Healix! The team at Healix would like to recognize and thank nurses across the nation for their dedication to the nursing profession and the time they sacrifice away from their loved ones to care for those in need. Healix Infusion Therapy and Collaborators Publish Real-World Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study Healix Infusion Therapy, LLC, announced today the publication of a collaborative study in theleading scientific journal, Open Forum Infectious Diseases. Thank You Healthcare Heroes! The team at Healix would like to thank all the healthcare heroes who are on the front lines treating patients during this unprecedented time with the COVID-19 crisis. State of Texas Association of Rheumatologists (STAR) Annual Meeting Meet the Healix team on February 28, at the State of Texas Association of Rheumatologists (STAR) Annual Meeting in Houston, TX. Tennessee Rheumatology Society (TRS) Annual Scientific Meeting Meet the Healix team on January 25, at the Tennessee Rheumatology Society (TRS) Annual Meeting in Franklin, TN. Celebrating 30 Years of Excellence Healix is proud to celebrate over 30 years of infusion excellence. American College of Rheumatology (ACR) Annual Meeting Meet the Healix team on November 10-12, 2019, at the American College of Rheumatology Annual Meeting in Atlanta, GA. American College of Allergy, Asthma, & Immunology (ACAAI) Annual Meeting Meet the Healix team in Houston, November 7-11, 2019, to learn about how we help practices like yours to provide unparalleled infusion patient care. American College of Gastroenterology (ACG) Annual Meeting Join Healix at the 2019 American College of Gastroenterology (ACG) Annual Meeting October 25-28, 2019. CHEST Annual Meeting Our team is excited to attend the 2019 CHEST conference in New Orleans, LA, October 21-23, 2019. IDWeek Visit our team at IDWeek October 2 – 6, 2019, in Washington D.C. to learn how we can help infectious disease practices like yours to provide unparalleled infusion patient care. Rheumatology Association of Minnesota and Dakotas (RA-MD) Join Healix in Bloomington, MN on September 28, 2019, for the Rheumatology Association of Minnesota and Dakotas (RA-MD) Annual Meeting. Congress of Clinical Rheumatology (CCR) Symposium Visit the Healix team at the Congress of Clinical Rheumatology (CCR) Symposium on September 26 – 29, 2019 in San Diego, CA. Illinois State Neurological Society (ISNS) Annual Meeting Meet the Healix team September 21, 2019, at the Illinois State Neurological Society (ISNS) Annual Meeting in Chicago, IL. Virginia Society of Rheumatologists 32nd Annual Scientific Meeting Healix will be attending and exhibiting at the 2019 Virginia Society of Rheumatologists 32nd Annual Scientific Meeting on September 20- 22, 2019, in Alexandria, VA. 12th Annual Perspectives in Rheumatic Diseases Annual Meeting Join Healix in Las Vegas, NV on September 20 – 21, 2019, for the 12th Annual Perspectives in Rheumatic Diseases Annual Meeting. Florida Society of Neurology (FSN) Annual Meeting Healix is proudly exhibiting at the upcoming Florida Society of Neurology Annual Meeting on September 13 -15, 2019, in Orlando, FL. National Organization of Rheumatology Managers (NORM) Annual Meeting Meet with the Healix team at the National Organization of Rheumatology Managers (NORM) Conference on September 12 – 14, 2019, in Grand Rapids, MI. Rheumatology Society of New Mexico (RSNM) Annual Meeting Healix will be exhibiting at the Rheumatology Society of New Mexico on September 7, 2019, in Albuquerque, NM. Missouri Kansas Neurological Society (MKNS) Annual Meeting Visit with the Healix team at Missouri Kansas Neurological Society Annual Meeting on September 7, 2019, in Branson, MO! Long Island Allergy & Asthma Society (LIAAS) Annual Meeting Join Healix in Montauk, New York, on September 6 – 8, 2019, for the 2019 Long Island Allergy & Asthma Society (LIAAS) Annual Meeting. Ohio Association of Rheumatology (OAR) Annual Meeting Healix is excited to exhibit at the upcoming Ohio Association of Rheumatology Annual Meeting on August 23-24, 2019, in Columbus, OH. GI Outlook 2019: The Practice Management Conference Meet the Healix team August 2-4, at the GI Outlook Conference in Hollywood, CA. Visit booth 21 to discover how working with Healix gives you the advantage! Healix Infusion Therapy Selected as Limited Distribution Network Partner for Cutaquig® Healix Infusion Therapy is pleased to announce that it has been selected as a limited distribution network partner for Cutaquig by Octapharma AG. Cutaquig, Octapharma’s new subcutaneous immune globulin, launches this week. Texas Infectious Diseases Society (TIDS) Annual Meeting Healix will be attending and exhibiting at the Texas Infectious Diseases Society (TIDS) Annual Meeting on June 7-9., 2019, in Lost Pines, Texas. Come and visit with our team to learn about. Arizona United Rheumatology Alliance (AURA) Annual Meeting Join Healix in sunny Sedona, Arizona, on May 31 – June 2, 2019, for the Arizona United Rheumatology Alliance (AURA) Annual Meeting. Our team would love to meet with you to discuss how. Georgia Society of Rheumatology (GSR) Annual Meeting Healix is proudly exhibiting at the upcoming Georgia Society of Rheumatology (GSR) Annual Meeting on May 31 – June 2, 2019, at the Ritz-Carlton, Reynols Plantation, in Greensboro, Georgia. If you are. Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting Are you attending the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting on May 28 – June 1 in Seattle, Washington? Come visit the Healix booth to discuss our expert infusion management. Digestive Disease Week (DDW) Come and visit with the Healix team at Digestive Disease Week (DDW) on May 19-21, 2019, in San Diego! We would love to meet with you to discuss how a Healix-managed. American Academy of Neurology (AAN) Annual Meeting Join Healix at the 2019 American Academy of Neurology (AAN) Annual Meeting on May 4-8, 2019, in Philadelphia, Pennsylvania. Our team of Healix representatives will be available at our booth. Healix Selects Citus Health to Digitally Transform Communication Streams and Care Coordination Healix, the nation’s leader in providing physician office-based infusion services, will implement the Citus Health digital solution suite to streamline multi-office healthcare communications and automate documentation workflows to provide. Healix Announces Strategic Partnership with WeInfuse SUGAR LAND, TX (December 6, 2018) – Healix, the nation’s leader in providing physician office-based infusion services, announces a strategic partnership with WeInfuse, the first and only end-to-end workflow. Healix Announces Strategic Partnership with DoseMe for Precision Dosing SUGAR LAND, TX (July 20, 2018) – Healix, the nation’s leader in physician office based infusion services, announced a strategic relationship with DoseMe, a precision dosing decision support platform specifically. TA Associates Announces Investment in Healix BOSTON and SUGAR LAND, Texas, December 18, 2017 – TA Associates, a leading global growth private equity firm, today announced that it has completed a strategic growth investment in Healix, a provider of outsourced. Healix Relocates to New State-of-the-Art Pharmacy Facility in Sugar Land, Texas SUGAR LAND, TX (July 28, 2017) – Healix Infusion Therapy, Inc. is proud to announce the relocation of its pharmacy operation to a new, state-of-the-art facility in Sugar Land, Texas. With more than 28. Healix is Now a National Provider of Trogarzo™ (ibalizumab-uiyk) SUGAR LAND, TX (July 28, 2017) – Healix® is Now a National Provider of Trogarzo™ (ibalizumab-uiyk). Trogarzo™ is a new humanized monoclonal antibody for the treatment of multidrug-resistant (MDR) HIV-1. Outpatient Treatment of Osteomyelitis with Telavancin SUGAR LAND, TX (July 14, 2017) – Gram-positive osteomyelitis was successfully treated with telavancin, as published in an article in The International Journal of Antimicrobial Agents. Healix® is Now a National Provider of Cuvitru® [Immune Globulin Subcutaneous (Human)] 20% SUGAR LAND, TX (March 20, 2017) – Healix has been selected among an exclusive number of distributers to become a national provider of Cuvitru [Immune Globulin Subcutaneous (Human)] 20%. Immunologists who partner with Healix. Dalbavancin: A Nationwide Outpatient Experience in Physician Office Infusion Centers SUGAR LAND, TX (May 23, 2016) – Dalbavancin is a long-acting lipoglycopeptide, approved for the treatment of acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria. A retrospective study was. Antimicrobial Regimen and Safety of Pediatric Outpatient Treatment in a POIC SUGAR LAND, TX (January 25, 2016) – Pediatric outpatient antimicrobial therapy (OPAT) is increasing, however, data on management, safety, and clinical outcomes are limited. A two-year retrospective, observational study was conducted of 64 pediatric. A 2-Year Analysis of 30-Day Hospital Readmissions and Cost Benefits of Septicemia OPAT in a POIC SAN DIEGO, CA (October 10, 2015) – Septicemia constitutes a major cause for 30-day hospital readmissions and is the most expensive condition treated in U.S. hospitals according to the Agency for Healthcare. Low Hospital Admission Rates Following POIC-Based Outpatient Treatment with Intravenous Antibiotics PHILADELPHIA, PA (October 10, 2014) – Outpatient antimicrobial therapy (OPAT) provided by a physician office infusion center revealed an overall low 30-day hospital admission rate of 6.8% compared to 26% previously reported. This collaborative, retrospective study. Comparison of Outpatient Antimicrobial Therapy (OPAT) in a POIC vs. Traditional Home Health Care PHILADELPHIA, PA (October 10, 2014) – Outpatient antimicrobial therapy (OPAT) in a physician office infusion center showed improved quality of care in contrast to a traditional home health care setting. A collaborative, retrospective study. Clinical Success in Outpatient Treatment of Complicated Urinary Tract Infections with Ertapenem SAN FRANCISCO, CA (October 4, 2013) – A retrospective database review was conducted of patients aged 18 and older receiving ertapenem therapy for UTI between July 1, 2010, and December 31, 2013. Seventy-five patients with a UTI diagnosis. Clinical & Economic Outcomes of Outpatient Parenteral Antimicrobial Therapy among Indigent Patients SAN FRANCISCO, CA (October 4, 2013) – This study is a report of clinical and economic outcome data of a hospital-funded Indigent Healthcare Program conducted in 11 Infectious Disease (ID) Physician Office Infusion Centers (POICs). Outpatient Parenteral Antimicrobial Therapy for Treatment of Complicated Intra-Abdominal Infections SAN FRANCISCO, CA (October 4, 2013) – A multi-center retrospective review of 120 patients receiving intravenous antibiotics (IVAB) for complicated intra-abdominal infections (IAI) in a physician office infusion center (POIC) was conducted to determine the. Outpatient Parenteral Antimicrobial Therapy for Treatment of Complicated Intra-Abdominal Infections SAN FRANCISCO, CA (October 9, 2013) – A multi-center review of 100 patients receiving Vancomycin was conducted to determine the effectiveness of patient monitoring and the recognition of adverse events in an outpatient setting. Successful Treatment of Polymicrobial Calcaneal Osteomyelitis SUGAR LAND, TX – Multidrug-resistant osteomyelitis was successfully treated with telavancin, rifampin, and meropenem, as published in an article in The Annals of Pharmacotherapy. Primary author was Mary Beth Brinkman. C. difficile-Associated Diarrhea Incidence & Outcomes in Physician Office Infusion Centers SAN DIEGO, CA (October 19, 2012) – A retrospective review of 1,352 patients treated at nine Infectious Disease POICs with intravenous antibiotics (IVAB) from January 1 to June 30, 2011, was conducted to assess the reduced risk level. Cost & Outcomes Comparison of Patients Whose Treatment Began in Infusion Center vs. After Discharge SAN DIEGO, CA (October 19, 2012) – A retrospective, multicenter review was conducted of eligible patients treated in the POIC from January 1- June 30, 2011, including 30-day follow-up to compare outcomes and costs in. Outcomes Comparison of IV Antimicrobials in an Office Infusion Center vs. Home Care Services SAN DIEGO, CA (October 19, 2012) – A retrospective review was conducted of randomly selected records for patients treated in four Infectious Disease POICs from January 2010-December 2011, to compare patient management and outcomes in. Utilization of IV Antimicrobials Over a One-Year Period in Physician Office Infusion Centers SAN DIEGO, CA (October 19, 2012) – A multi-center retrospective review of 11,616 patients receiving intravenous antimicrobials (IVAM) was conducted to determine utilization of IVAM in POICs and efficient device utilization. In the 65 participating. Successful, Cost-Saving Outpatient Parenteral Antimicrobial Therapy Following Hospital Discharge SAN DIEGO, CA (October 19, 2012) – A retrospective pilot study was conducted of all patients, from January 2011 through April 2012, receiving OPAT under an indigent healthcare program (a hospital-funded program providing IV antibiotics through. Low Rates of C. difficile Associated Diarrhea in Patients Receiving IVAB in the Outpatient Setting BOSTON, MA (October 21, 2011) – Patients receiving intravenous antibiotics in seven Infectious Disease Physician Office Infusion Centers (POICs) experienced a low rate of Clostridium difficile associated diarrhea (2.5 per 10,000 patient days). Of the 934. Low Readmission and Recurrence Rates of Bacteremia, Endocarditis & Osteomyelitis in Infusion Centers BOSTON, MA (October 21, 2011) – A multi-center retrospective review of 203 patients treated with long term intravenous antibiotic therapy in physician office infusion centers (POICs) is effective with clinical success rates of 93% in bacteremia, 88%. Treatment with IV Antibiotics in an Outpatient POIC Shows Successful Outcomes and Cost Savings BOSTON, MA (October 21, 2011) – A 3-year trend analysis was conducted of patients initiated on intravenous antibiotics (IVAB) in an Infectious Disease Physician Office Infusion Center (POIC) during the years 2008 – 2010 for. Telavancin Treatment in the Outpatient Setting is Effective BOSTON, MA (October 21, 2011) – In a 16 month period, 47 patients were treated with telavancin in 15 physician office infusion centers (POICs) with indications for acute bacterial skin and skin structure infections (24), osteomyelitis (19), sepsis (3). Healix Launches New App to Boost Client Efficiency SUGAR LAND, TX (January 1, 2011) – Healix announced the official launch of the iPhone® compatible Healix App, a tool for on-the-go physicians to track formulary options with payer reimbursement data. How Can We Help You? Get in touch with us or explore our offerings. "Establishing a relationship with Healix has allowed us to provide our patients with outstanding care while being able to control the clinical situation and achieve the best possible outcomes." Andrew Krinsky, MD Infectious Diseases Associates, Sarasota, Florida Contact usPrivacy PolicyTerms and conditionsADP employee loginClient loginPaycom Employee Login web design © Healix Infusion Therapy